Lindsay M. Stratchko, E. K. Koepsel, T. Ziemlewicz, E. Knott, J. Hinshaw, S. Wells, P. Laeseke, Fred T. Lee Jr
Chronic liver disease predisposes patients to the development of hepatocellular carcinoma (HCC), and the degree of liver dysfunction helps dictate the management of patients with primary hepatic malignancy. Percutaneous ablation is an increasingly utilized treatment modality for patients with hepatocellular carcinoma who are poor surgical candidates, particularly when treatment goals include sparing hepatic parenchyma in the setting of hepatic dysfunction. Various thermal and non-thermal ablation modalities have historically been used to treat HCC. With advances in ablation technology, modern microwave (MW) ablation systems have become increasingly utilized in HCC as well as hepatic metastatic disease management due to larger and more predictable ablation zones. The evolution of ablation technology has resulted in the growth of ablation as a safe and effective treatment option for patients with primary and secondary liver tumors.
{"title":"Microwave Ablation of Hepatocellular Carcinoma and Liver Metastases: Challenges, Opportunities, and Future Directions","authors":"Lindsay M. Stratchko, E. K. Koepsel, T. Ziemlewicz, E. Knott, J. Hinshaw, S. Wells, P. Laeseke, Fred T. Lee Jr","doi":"10.1055/s-0041-1741521","DOIUrl":"https://doi.org/10.1055/s-0041-1741521","url":null,"abstract":"Chronic liver disease predisposes patients to the development of hepatocellular carcinoma (HCC), and the degree of liver dysfunction helps dictate the management of patients with primary hepatic malignancy. Percutaneous ablation is an increasingly utilized treatment modality for patients with hepatocellular carcinoma who are poor surgical candidates, particularly when treatment goals include sparing hepatic parenchyma in the setting of hepatic dysfunction. Various thermal and non-thermal ablation modalities have historically been used to treat HCC. With advances in ablation technology, modern microwave (MW) ablation systems have become increasingly utilized in HCC as well as hepatic metastatic disease management due to larger and more predictable ablation zones. The evolution of ablation technology has resulted in the growth of ablation as a safe and effective treatment option for patients with primary and secondary liver tumors.","PeriodicalId":91014,"journal":{"name":"Digestive disease interventions","volume":"81 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83873824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Simon Long, D. Fernando, Christina Boyd, J. Katrivesis, Harold Park
In patients requiring nutritional support, enteral nutrition has been shown to have many benefits, including improved long-term outcomes, when compared to parenteral alternatives. Given our baseline comfort with medical imaging and knowledge of anatomy, Interventional Radiologists can support a patient's caloric needs and circumvent more invasive surgical methods for placing feeding tubes.
{"title":"Interventional Techniques to Support Enteral Nutrition","authors":"Simon Long, D. Fernando, Christina Boyd, J. Katrivesis, Harold Park","doi":"10.1055/s-0042-1742295","DOIUrl":"https://doi.org/10.1055/s-0042-1742295","url":null,"abstract":"In patients requiring nutritional support, enteral nutrition has been shown to have many benefits, including improved long-term outcomes, when compared to parenteral alternatives. Given our baseline comfort with medical imaging and knowledge of anatomy, Interventional Radiologists can support a patient's caloric needs and circumvent more invasive surgical methods for placing feeding tubes.","PeriodicalId":91014,"journal":{"name":"Digestive disease interventions","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72453267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Smolock, Osmani Deochand, W. Rilling, P. Patel, E. Hohenwalter, S. White, M. Scheidt
Abstract We sought to evaluate differences in outcomes between double versus triple transarterial chemoembolization (TACE). TACEs over a 1-year period were retrospectively reviewed and divided into two groups: double and triple. Imaging response and complications were made on a per-procedure basis. Student's t -test was used to calculate differences in continuous variables, and chi-square test was used to calculate differences in categorical values.Overall tumor response was similar between the two groups, and there were no significant differences in complications between groups. Outcomes are similar between double and triple conventional TACE, suggesting that adding a third drug may only contribute to cost.
{"title":"Comparison of Outcomes with Triple-Regimen versus Double-Regimen Transarterial Chemoembolization","authors":"A. Smolock, Osmani Deochand, W. Rilling, P. Patel, E. Hohenwalter, S. White, M. Scheidt","doi":"10.1055/s-0042-1756460","DOIUrl":"https://doi.org/10.1055/s-0042-1756460","url":null,"abstract":"Abstract We sought to evaluate differences in outcomes between double versus triple transarterial chemoembolization (TACE). TACEs over a 1-year period were retrospectively reviewed and divided into two groups: double and triple. Imaging response and complications were made on a per-procedure basis. Student's t -test was used to calculate differences in continuous variables, and chi-square test was used to calculate differences in categorical values.Overall tumor response was similar between the two groups, and there were no significant differences in complications between groups. Outcomes are similar between double and triple conventional TACE, suggesting that adding a third drug may only contribute to cost.","PeriodicalId":91014,"journal":{"name":"Digestive disease interventions","volume":"55 1","pages":"159 - 162"},"PeriodicalIF":0.0,"publicationDate":"2022-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79700060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Dölle, H. Wedemeyer, M. Gebel, A. Potthoff, S. Zender
Background Splenic cysts are rare and occur in 0.5 to 2% of the population. They are usually asymptomatic and do not require therapy. In case of symptomatic nonparasitic splenic cysts, potential therapy includes partial splenectomy or laparoscopic cyst de-roofing as well as ultrasound-guided sclerotherapy with 1% polidocanol or 10% sodium chloride (NaCl) as an interventional alternative. So far, single-session sclerotherapy of symptomatic nonparasitic cysts is recommended only if clear-transparent cyst fluid is aspirated. Materials and Methods We report a case series of 17 patients with symptomatic macroscopically turbid nonparasitic splenic cyst fluid who underwent ultrasound-guided fine needle sclerotherapy with either polidocanol ± 10% NaCl (n = 12) or 10% NaCl alone (n = 5) and a follow-up of a maximum of 12 years after first intervention. Clinical, sonographic, and laboratory chemistry data were recorded at baseline and during the follow-up. Results The mean follow-up time was 43.65 ± 40.18 months. At the end of the follow-up, a 79% reduction of cyst size was achieved. The maximum size reduction in the polidocanol group was 76 ± 18% and 84 ± 21% in the sodium chloride group (p >0.05). At the end of follow-up, 15 out of the 17 patients did not have any further symptoms. Despite the cystic fluid being turbid, it was hardly possible to detect a microbiological superinfection. Conclusion Sclerotherapy of splenic cysts leads to a significant size regression in all patients, independent of the sclerotherapy agent used with fewer systemic toxic side effects of polidocanol treatment. It was shown that in a tertiary care center with significant experience, sclerotherapy of splenic cysts is also safe and successful and can lead to a drastic regression of cyst size and symptoms. This shows that interventional therapy is a good alternative to surgical procedures.
{"title":"Sclerotherapy of Symptomatic Nonparasitic Splenic Cysts: Excellent Long-Term Treatment Response'","authors":"M. Dölle, H. Wedemeyer, M. Gebel, A. Potthoff, S. Zender","doi":"10.1055/s-0041-1742245","DOIUrl":"https://doi.org/10.1055/s-0041-1742245","url":null,"abstract":"\u0000 Background Splenic cysts are rare and occur in 0.5 to 2% of the population. They are usually asymptomatic and do not require therapy. In case of symptomatic nonparasitic splenic cysts, potential therapy includes partial splenectomy or laparoscopic cyst de-roofing as well as ultrasound-guided sclerotherapy with 1% polidocanol or 10% sodium chloride (NaCl) as an interventional alternative. So far, single-session sclerotherapy of symptomatic nonparasitic cysts is recommended only if clear-transparent cyst fluid is aspirated.\u0000 Materials and Methods We report a case series of 17 patients with symptomatic macroscopically turbid nonparasitic splenic cyst fluid who underwent ultrasound-guided fine needle sclerotherapy with either polidocanol ± 10% NaCl (n = 12) or 10% NaCl alone (n = 5) and a follow-up of a maximum of 12 years after first intervention. Clinical, sonographic, and laboratory chemistry data were recorded at baseline and during the follow-up.\u0000 Results The mean follow-up time was 43.65 ± 40.18 months. At the end of the follow-up, a 79% reduction of cyst size was achieved. The maximum size reduction in the polidocanol group was 76 ± 18% and 84 ± 21% in the sodium chloride group (p >0.05). At the end of follow-up, 15 out of the 17 patients did not have any further symptoms. Despite the cystic fluid being turbid, it was hardly possible to detect a microbiological superinfection.\u0000 Conclusion Sclerotherapy of splenic cysts leads to a significant size regression in all patients, independent of the sclerotherapy agent used with fewer systemic toxic side effects of polidocanol treatment. It was shown that in a tertiary care center with significant experience, sclerotherapy of splenic cysts is also safe and successful and can lead to a drastic regression of cyst size and symptoms. This shows that interventional therapy is a good alternative to surgical procedures.","PeriodicalId":91014,"journal":{"name":"Digestive disease interventions","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89954008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Tantawi, S. Shamimi-Noori, C. Shaw, J. Eisenbrey
Abstract Locoregional therapies (LRTs) are an essential management tool in the treatment of primary liver cancers or metastatic liver disease. LRTs include curative and palliative modalities. Monitoring treatment response of LRTs is crucial for maximizing benefit and improving clinical outcomes. Clinical use of contrast-enhanced ultrasound (CEUS) was introduced more than two decades ago. Its portability, cost effectiveness, lack of contraindications and safety make it an ideal tool for treatment monitoring in numerous situations. Two-dimensional dynamic CEUS has been proved to be equivalent to the current imaging standard in the guidance of LRTs, assessment of their adequacy, and detection of early tumor recurrence. Recent technical advances in ultrasound transducers and image processing have made 3D CEUS scanning widely available on most commercial ultrasound systems. 3D scanning offers a broad multiplanar view of anatomic structures, overcoming many limitations of two-dimensional scanning. Furthermore, many ultrasound systems provide real-time dynamic 3D CEUS, also known as 4D CEUS. Volumetric CEUS has shown to perform better than 2D CEUS in the assessment and monitoring of some LRTs. CEUS presents a valid alternative to the current imaging standards with reduced cost and decreased risk of complications. Future efforts will be directed toward refining the utility of 4D CEUS through approaches such as multi-parametric quantitative analysis and machine learning algorithms.
{"title":"State of the Art: Contrast Enhanced 4D Ultrasound to Monitor or Assess Locoregional Therapies","authors":"M. Tantawi, S. Shamimi-Noori, C. Shaw, J. Eisenbrey","doi":"10.1055/s-0041-1741520","DOIUrl":"https://doi.org/10.1055/s-0041-1741520","url":null,"abstract":"Abstract Locoregional therapies (LRTs) are an essential management tool in the treatment of primary liver cancers or metastatic liver disease. LRTs include curative and palliative modalities. Monitoring treatment response of LRTs is crucial for maximizing benefit and improving clinical outcomes. Clinical use of contrast-enhanced ultrasound (CEUS) was introduced more than two decades ago. Its portability, cost effectiveness, lack of contraindications and safety make it an ideal tool for treatment monitoring in numerous situations. Two-dimensional dynamic CEUS has been proved to be equivalent to the current imaging standard in the guidance of LRTs, assessment of their adequacy, and detection of early tumor recurrence. Recent technical advances in ultrasound transducers and image processing have made 3D CEUS scanning widely available on most commercial ultrasound systems. 3D scanning offers a broad multiplanar view of anatomic structures, overcoming many limitations of two-dimensional scanning. Furthermore, many ultrasound systems provide real-time dynamic 3D CEUS, also known as 4D CEUS. Volumetric CEUS has shown to perform better than 2D CEUS in the assessment and monitoring of some LRTs. CEUS presents a valid alternative to the current imaging standards with reduced cost and decreased risk of complications. Future efforts will be directed toward refining the utility of 4D CEUS through approaches such as multi-parametric quantitative analysis and machine learning algorithms.","PeriodicalId":91014,"journal":{"name":"Digestive disease interventions","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85879497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abstract Laparoscopic liver resection has evolved from a technique to remove small anterior liver lesions with smaller incisions to a major method for the performance of almost every type of liver resection.
腹腔镜肝切除术已经从一种以较小切口切除肝前小病变的技术发展成为几乎所有类型肝切除术的主要方法。
{"title":"Laparoscopic Liver Resection: Surgical Techniques","authors":"B. Sullivan, R. Wolf, Z. Jutric","doi":"10.1055/s-0041-1742153","DOIUrl":"https://doi.org/10.1055/s-0041-1742153","url":null,"abstract":"Abstract Laparoscopic liver resection has evolved from a technique to remove small anterior liver lesions with smaller incisions to a major method for the performance of almost every type of liver resection.","PeriodicalId":91014,"journal":{"name":"Digestive disease interventions","volume":"110 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85349174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abstract Sarcopenia is a major sequela of cirrhosis, contributing to significant morbidity and mortality. Advances in body composition analysis using medical imaging have begun to identify changes in skeletal muscle and fat that are prognostic of the impact of sarcopenia on medical outcomes in cirrhosis and other pathologies. Recently, observational studies have shown a correlation between transjugular intrahepatic portosystemic shunt (TIPS) creation and a reversal of the progressive muscle loss in cirrhosis. This reversal is also associated with improved clinical outcomes and survival. This review summarizes current understanding of cirrhotic sarcopenia, and discusses the implications of TIPS creation in reversing this process.
{"title":"Sarcopenia of Cirrhosis and the Therapeutic Potential of Transjugular Intrahepatic Portosystemic Shunt Creation","authors":"B. Schlansky, K. Farsad","doi":"10.1055/s-0041-1742214","DOIUrl":"https://doi.org/10.1055/s-0041-1742214","url":null,"abstract":"Abstract Sarcopenia is a major sequela of cirrhosis, contributing to significant morbidity and mortality. Advances in body composition analysis using medical imaging have begun to identify changes in skeletal muscle and fat that are prognostic of the impact of sarcopenia on medical outcomes in cirrhosis and other pathologies. Recently, observational studies have shown a correlation between transjugular intrahepatic portosystemic shunt (TIPS) creation and a reversal of the progressive muscle loss in cirrhosis. This reversal is also associated with improved clinical outcomes and survival. This review summarizes current understanding of cirrhotic sarcopenia, and discusses the implications of TIPS creation in reversing this process.","PeriodicalId":91014,"journal":{"name":"Digestive disease interventions","volume":"226 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89187439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abstract The first endoscope was created in 1805 by Philip Bozini in Germany. This endoscope was known as “Lichtleiter,” a light guiding instrument. In the 1950s, the first models of fiberoptic endoscopes were introduced. Since then, the technology associated with endoscopic surgery has grown by leaps and bounds. This article aims to explore current operating platforms and emerging technology associated with endoscopic surgery.
{"title":"Endoscopic Operating Platforms and Advancements","authors":"I. Sethi, Amy Rosenbluth","doi":"10.1055/s-0041-1740599","DOIUrl":"https://doi.org/10.1055/s-0041-1740599","url":null,"abstract":"Abstract The first endoscope was created in 1805 by Philip Bozini in Germany. This endoscope was known as “Lichtleiter,” a light guiding instrument. In the 1950s, the first models of fiberoptic endoscopes were introduced. Since then, the technology associated with endoscopic surgery has grown by leaps and bounds. This article aims to explore current operating platforms and emerging technology associated with endoscopic surgery.","PeriodicalId":91014,"journal":{"name":"Digestive disease interventions","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81799956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abstract As many as 500,000 cholecystectomies are performed per year in the United States. Frail patients are at higher risk from cholecystectomy, with reported postoperative complication and mortality rates as high as 31 and 5% in patients older than 75 years. Percutaneous cholecystostomy drainage is commonly employed in high-risk patients with cholecystitis, with over 12,000 cases performed annually. Cholecystostomy, however, is not a definitive treatment, with up to 30% of patients having a recurrent episode of cholecystitis within 4 months after tube removal. Gallbladder cryoablation has emerged as a minimally invasive procedure that achieves transmural gallbladder wall necrosis in a single session resulting in gallbladder fibrosis and involution. Early clinical data have been promising, with reported technical success of 86% and clinical success of 100% at up to 500 days of follow-up. Several challenges and unknowns remain, however, including optimal patient selection and procedural technique, the potential need for adjunct procedures to occlude the cystic duct, the implications of the immunostimulatory effects of cryoablation, and the impact of the presence of gallstones on outcomes. This article reviews the rationale behind gallbladder cryoablation, updates early clinical outcomes, and discusses the challenges that remain for the adoption of the technique for the treatment of benign gallbladder disease.
{"title":"Gallbladder Cryoablation: Clinical and Technical Considerations","authors":"H. McGregor","doi":"10.1055/s-0041-1742101","DOIUrl":"https://doi.org/10.1055/s-0041-1742101","url":null,"abstract":"Abstract As many as 500,000 cholecystectomies are performed per year in the United States. Frail patients are at higher risk from cholecystectomy, with reported postoperative complication and mortality rates as high as 31 and 5% in patients older than 75 years. Percutaneous cholecystostomy drainage is commonly employed in high-risk patients with cholecystitis, with over 12,000 cases performed annually. Cholecystostomy, however, is not a definitive treatment, with up to 30% of patients having a recurrent episode of cholecystitis within 4 months after tube removal. Gallbladder cryoablation has emerged as a minimally invasive procedure that achieves transmural gallbladder wall necrosis in a single session resulting in gallbladder fibrosis and involution. Early clinical data have been promising, with reported technical success of 86% and clinical success of 100% at up to 500 days of follow-up. Several challenges and unknowns remain, however, including optimal patient selection and procedural technique, the potential need for adjunct procedures to occlude the cystic duct, the implications of the immunostimulatory effects of cryoablation, and the impact of the presence of gallstones on outcomes. This article reviews the rationale behind gallbladder cryoablation, updates early clinical outcomes, and discusses the challenges that remain for the adoption of the technique for the treatment of benign gallbladder disease.","PeriodicalId":91014,"journal":{"name":"Digestive disease interventions","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79153201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abstract Variceal hemorrhage is a morbid condition that frequently mandates the involvement of interventional radiology to achieve successful and sustained hemostasis. Primary image-guided therapies for variceal hemorrhage include a transjugular intrahepatic portosystemic shunt and transvenous obliteration. Knowledge of variceal pathophysiology and anatomy, current techniques, and the evidence supporting therapeutic selection is paramount to successful patient outcomes. The purpose of this review is to provide the reader a framework of the available literature on image-guided management of bleeding varices to assist in clinical management.
{"title":"Variceal Hemorrhage: Decompression, Obliteration, or Both?","authors":"B. McCafferty, H. E. Khudari, A. Salei, A. Gunn","doi":"10.1055/s-0041-1742100","DOIUrl":"https://doi.org/10.1055/s-0041-1742100","url":null,"abstract":"Abstract Variceal hemorrhage is a morbid condition that frequently mandates the involvement of interventional radiology to achieve successful and sustained hemostasis. Primary image-guided therapies for variceal hemorrhage include a transjugular intrahepatic portosystemic shunt and transvenous obliteration. Knowledge of variceal pathophysiology and anatomy, current techniques, and the evidence supporting therapeutic selection is paramount to successful patient outcomes. The purpose of this review is to provide the reader a framework of the available literature on image-guided management of bleeding varices to assist in clinical management.","PeriodicalId":91014,"journal":{"name":"Digestive disease interventions","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89609018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：